Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nadunolimab for Current or Former Smokers With High-risk Lung Nodules
NCT07284485Phase 2Recruiting
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nadunolimab in Pulmonary nodule. Started May 2026; status: recruiting.
02
Drugs
nadunolimab
03
Conditions
Pulmonary nodule
Beyond the preview
Go deeper on NCT07284485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07284485.